KZIA - Kazia Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

102.9M

Cash

3.563M

Avg Qtr Burn

-3.171M

Short % of Float

1.44%

Insider Ownership

0.00%

Institutional Own.

11.00%

Qtr Updated

12/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Paxalisib (GDC-0084) (PI3K pathway) Details Glioblastoma	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Paxalisib (GDC-0084) (PI3K pathway) Details Glioma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Paxalisib (GDC-0084) (PI3K pathway) Details primary central nervous system lymphomas	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EVT801 Details Solid tumor/s, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cantrixil (TRX-E-002-1) Details Ovarian cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.